Review Article| Volume 47, ISSUE 9, P2212-2219, September 2021

Download started.


Concerning CT features predict outcome of treatment in patients with malignant peritoneal mesothelioma

Published:April 14, 2021DOI:



      Malignant peritoneal mesothelioma is an aggressive local-regional disease with dissemination to all parts of the abdomen and pelvis at the time of diagnosis. Recently, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been used and improved survival was documented with this local-regional treatment strategy.


      Concerning CT features were described that were specific for malignant peritoneal mesothelioma. The incidence of concerning radiologic features and their impact on survival was determined. The prognostic assessment of concerning CT features was compared to the peritoneal cancer index (PCI) and the completeness of cytoreduction score (CC score).


      One hundred patients with a preoperative CT were evaluated by 11 concerning CT features. The incidence of these CT features varied between 5% and 41%. Nine of the 11 CT features statistically significantly predicted a reduced survival in these patients treated in a uniform manner. When concerning radiologic features were grouped as none, a single feature or two or more features, a significant composite analysis was achieved with p < 0.001. The prognostic information from concerning CT features compared favorably with the prognostic implications of PCI and CC score.


      The availability of the concerning CT features to predict prognosis at the initiation of treatments for malignant peritoneal mesothelioma shows that this radiologic assessment may be of great value to the clinician in planning a treatment strategy for an individual patient.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Surgical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Sugarbaker P.H.
        • van der Speeten K.
        An overview of peritonectomy, visceral resection, and therapeutic laparoscopy for peritoneal surface malignancy.
        in: Sugarbaker P.H. Cytoreductive surgery & perioperative chemotherapy for peritoneal surface malignancy. Textbook and video atlas. second ed. Cine-Med Publishing, Woodbury, CT2017: 17-46
        • Van der Speeten K.
        • Stuart O.A.
        • Sugarbaker P.H.
        Cancer chemotherapy for peritoneal metastases: pharmacology and treatment.
        in: Sugarbaker P.H. Cytoreductive surgery & perioperative chemotherapy for peritoneal surface malignancy. Textbook and video atlas. second ed. Cine-Med Publishing, Woodbury, CT2017: 47-82
        • Sugarbaker P.H.
        • Sardi A.
        • Brown G.
        • Dromain C.
        • Rousset P.
        • Jelinek J.S.
        Concerning CT features used to select patients for treatment of peritoneal metastases, a pictoral essay.
        Int J Hyperther. 2017; 33: 497-504
        • Jacquet P.
        • Sugarbaker P.H.
        Current methodologies for clinical assessment of patients with peritoneal carcinomatosis.
        J Exp Clin Canc Res. 1996; 15: 49-58
        • Jacquet P.
        • Jelinek J.S.
        • Chang D.
        • Koslowe P.
        • Sugarbaker P.H.
        Abdominal computed tomographic scan in the selection of patients with mucinous peritoneal carcinomatosis for cytoreductive surgery.
        J Am Coll Surg. 1995; 181: 530-538
        • Yan T.D.
        • Welch L.
        • Black D.
        • Sugarbaker P.H.
        A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma.
        Ann Oncol. 2007; 18: 827-834
        • Yan T.D.
        • Haveric N.
        • Carmignani P.
        • Chang D.
        • Sugarbaker P.H.
        Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy.
        Cancer. 2005; 15: 839-849
        • Rivard J.D.
        • Temple W.J.
        • McConnell Y.J.
        • et al.
        Preoperative computed tomography does not predict resectability in peritoneal carcinomatosis.
        Am J Surg. 2014; 207: 760-765
        • Sugarbaker P.H.
        • Turaga K.K.
        • Alexander Jr., H.R.
        • Deraco M.
        • Hesdorffer M.
        Management of malignant peritoneal mesothelioma using cytoreductive surgery and perioperative chemotherapy.
        J Oncol Pract. 2016; 12: 928-935
        • Antman K.H.
        • Blum R.H.
        • Greenberger J.S.
        • et al.
        Multimodality therapy for malignant mesothelioma based on a study of natural history.
        Am J Med. 1980; 68: 356-362
        • Jeune F.
        • Brouquet A.
        • Caramella C.
        • et al.
        Cardiophrenic angle lymph node is an indicator of metastatic spread but not specifically peritoneal carcinomatosis in colorectal cancer patients: results of a prospective validation study in 91 patients.
        Eur J Surg Oncol. 2016; 42: 861-868
        • Elias D.
        • Borget I.
        • Farron M.
        • et al.
        Prognostic significance of visible cardiophrenic angle lymph nodes in the presence of peritoneal metastases from colorectal cancers.
        Eur J Surg Oncol. 2013; 39: 1214-1218
        • Llanos M.D.
        • Sugarbaker P.H.
        Symptoms, signs and radiologic findings in patients having reoperative surgery for malignant peritoneal mesothelioma.
        Eur J Surg Oncol. 2017; 43: 138-143
        • Low R.N.
        • Barone R.M.
        Combined diffusion-weighted and gadolinium-enhanced MRI can accurately predict the peritoneal cancer index preoperatively in patients being considered for cytoreductive surgical procedures.
        Ann Surg Oncol. 2012; 19: 1394-1401
        • da Silva R.G.
        • Sugarbaker P.H.
        Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer.
        J Am Coll Surg. 2006; 203: 878-886
        • Sugarbaker P.H.
        Pseudomyxoma peritonei and peritoneal metastases from appendiceal malignancy.
        in: Sugarbaker P.H. Cytoreductive surgery & perioperative chemotherapy for peritoneal surface malignancy. Textbook and video atlas. second ed. Cine-Med Publishing, Woodbury, CT2017: 109-132